NCT06427213 2024-05-23This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaHenan Cancer HospitalPhase 2 Not yet recruiting41 enrolled